No headlines found.
Globe Newswire (Fri, 7-Aug 7:00 AM ET)
Gyre Therapeutics Appoints Three New Members to its Board of Directors
Globe Newswire (Thu, 16-Jul 4:05 PM ET)
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
Gyre Therapeutics trades on the NASDAQ stock market under the symbol GYRE.
As of August 25, 2026, GYRE stock price climbed to $6.71 with 31,348 million shares trading.
GYRE has a beta of 1.26, meaning it tends to be more sensitive to market movements. GYRE has a correlation of 0.11 to the broad based SPY ETF.
GYRE has a market cap of $748.09 million. This is considered a Small Cap stock.
Last quarter Gyre Therapeutics reported $29 million in Revenue and -$.12 earnings per share. This beat revenue expectation by $3 million and missed earnings estimates by -$.06.
The top ETF exchange traded funds that GYRE belongs to (by Net Assets): VTI, IWM, VXF, IWO, SCHA.
GYRE has underperformed the market in the last year with a return of -18.0%, while SPY returned +19.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in GYRE shares. However, GYRE has outperformed the market in the last 3 month and 2 week periods, returning +10.7% and -0.1%, while SPY returned +2.9% and -1.0%, respectively. This indicates GYRE has been having a stronger performance recently.
GYRE support price is $6.22 and resistance is $6.66 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GYRE shares will trade within this expected range on the day.
